{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:25:51Z","timestamp":1792113951005,"version":"4.4.0"},"reference-count":68,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UK Department of Health and Social Care","award":["C72219"],"award-info":[{"award-number":["C72219"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder causing the degeneration of motor neurons in the spinal cord. Recent studies suggest greater effectiveness of treatment in the presymptomatic stage. This systematic review synthesises findings from 37 studies (and 3 overviews) of newborn screening for SMA published up to November 2023 across 17 countries to understand the methodologies used; test accuracy performance; and timing, logistics and feasibility of screening. All studies screened for the homozygous deletion of SMN1 exon 7. Most (28 studies) used RT-PCR as the initial test on dried blood spots (DBSs), while nine studies also reported second-tier tests on DBSs for screen-positive cases. Babies testing positive on DBSs were referred for confirmatory testing via a range of methods. Observed SMA birth prevalence ranged from 1 in 4000 to 1 in 20,000. Most studies reported no false-negative or false-positive cases (therefore had a sensitivity and specificity of 100%). Five studies reported either one or two false-negative cases each (total of six cases; three compound heterozygotes and three due to system errors), although some false-negatives may have been missed due to lack of follow-up of negative results. Eleven studies reported false-positive cases, some being heterozygous carriers or potentially related to heparin use. Time to testing and treatment varied between studies. In conclusion, several countries have implemented newborn screening for SMA in the last 5 years using a variety of methods. Implementation considerations include processes for timely initial and confirmatory testing, partnerships between screening and neuromuscular centres, and timely treatment initiation.<\/jats:p>","DOI":"10.3390\/ijns10030049","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T11:12:49Z","timestamp":1721128369000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-8103","authenticated-orcid":false,"given":"Katy","family":"Cooper","sequence":"first","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Nalbant","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-2516","authenticated-orcid":false,"given":"Anthea","family":"Sutton","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Harnan","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Thokala","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-7817","authenticated-orcid":false,"given":"Jim","family":"Chilcott","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisdair","family":"McNeill","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-0309","authenticated-orcid":false,"given":"Alice","family":"Bessey","sequence":"additional","affiliation":[{"name":"School of Medicine and Population Health, University of Sheffield, Sheffield S1 4DA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal Muscular Atrophy: In the Challenge Lies a Solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajmg.a.30251","article-title":"Homozygous SMN1 Deletions in Unaffected Family Members and Modification of the Phenotype by SMN2","volume":"130A","author":"Prior","year":"2004","journal-title":"Am. J. Med. Genet. Pt. A"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","article-title":"Risdiplam: A Review in Spinal Muscular Atrophy","volume":"36","author":"Paik","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","article-title":"Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy","volume":"36","author":"Blair","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene Abeparvovec for Presymptomatic Infants with Two Copies of SMN2 at Risk for Spinal Muscular Atrophy Type 1: The Phase III SPR1NT Trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41431-023-01469-8","article-title":"A Framework for Evaluating Long-Term Impact of Newborn Screening","volume":"32","author":"Kalkman","year":"2024","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_9","first-page":"A200","article-title":"Feasibility and Uptake of Newborn Screening for Spinal Muscular Atrophy in the UK","volume":"108","author":"Horton","year":"2023","journal-title":"Arch. Dis. Child."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"19922","DOI":"10.1038\/s41598-021-99496-2","article-title":"Three Years Pilot of Spinal Muscular Atrophy Newborn Screening Turned into Official Program in Southern Belgium","volume":"11","author":"Boemer","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.nmd.2019.02.003","article-title":"Newborn Screening for SMA in Southern Belgium","volume":"29","author":"Boemer","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_12","first-page":"S73","article-title":"Organisational, Ethical, and Regulatory Considerations When Setting up an NBS Program","volume":"9","author":"Betts","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-021-01783-8","article-title":"Newborn Screening for Spinal Muscular Atrophy in Germany: Clinical Results after 2 Years","volume":"16","author":"Vill","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41431-019-0476-4","article-title":"High-Throughput Genetic Newborn Screening for Spinal Muscular Atrophy by Rapid Nucleic Acid Extraction from Dried Blood Spots and 384-Well QPCR","volume":"28","author":"Czibere","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-200475","article-title":"Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening\u2014Opportunity or Burden?","volume":"7","author":"Vill","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One Year of Newborn Screening for SMA\u2014Results of a German Pilot Project","volume":"6","author":"Vill","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JND-221577","article-title":"Newbornscreening SMA\u2014From Pilot Project to Nationwide Screening in Germany","volume":"10","author":"Blaschek","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tesorero, R., Janda, J., Horster, F., Feyh, P., Mutze, U., Hauke, J., Schwarz, K., Kunz, J.B., Hoffmann, G.F., and Okun, J.G. (2023). A High-Throughput Newborn Screening Approach for SCID, SMA, and SCD Combining Multiplex QPCR and Tandem Mass Spectrometry. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0283024"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jmg-2022-108873","article-title":"Experience of a 2-Year Spinal Muscular Atrophy NBS Pilot Study in Italy: Towards Specific Guidelines and Standard Operating Procedures for the Molecular Diagnosis","volume":"60","author":"Abiusi","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_20","first-page":"55","article-title":"Newborn Screening (NBS) Program for the Simultaneous Early Diagnosis of Spinal Muscular Atrophy (SMA) and Severe Combined Immunodeficiency (SCID) in Liguria Region, Italy","volume":"41","author":"Bruno","year":"2022","journal-title":"Acta Myol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gailite, L., Sterna, O., Konika, M., Isakovs, A., Isakova, J., Micule, I., Setlere, S., Diriks, M., and Auzenbaha, M. (2022). New-Born Screening for Spinal Muscular Atrophy: Results of a Latvian Pilot Study. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8010015"},{"key":"ref_22","first-page":"26","article-title":"Pilot Study on Newborn Screening for Spinal Muscular Atrophy","volume":"24","author":"Fonseca","year":"2024","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_23","first-page":"678","article-title":"Implementation of Newborn Screening for Spinal Muscular Atrophy in Poland\u2014One Year Experience","volume":"31","author":"Gos","year":"2023","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0140-6736(23)01281-3","article-title":"Universal Newborn Screening for Spinal Muscular Atrophy in Ukraine","volume":"402","author":"Olkhovych","year":"2023","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.nmd.2023.07.102","article-title":"P220 National Newborn Screening for SMA in Norway","volume":"33","author":"Wallace","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/dmcn.15117","article-title":"Integrating Newborn Screening for Spinal Muscular Atrophy into Health Care Systems: An Australian Pilot Programme","volume":"64","author":"Kariyawasam","year":"2022","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","article-title":"The Implementation of Newborn Screening for Spinal Muscular Atrophy: The Australian Experience","volume":"22","author":"Kariyawasam","year":"2020","journal-title":"Genet. Med."},{"key":"ref_28","first-page":"57","article-title":"Evaluation of the NSW Newborn Screening Pathway for SMA","volume":"26","author":"Wotton","year":"2023","journal-title":"Twin Res. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Shum, B.O.V., Henner, I., Cairns, A., Pretorius, C., Wilgen, U., Barahona, P., Ungerer, J.P.J., and Bennett, G. (2023). Technical Feasibility of Newborn Screening for Spinal Muscular Atrophy by Next-Generation DNA Sequencing. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1095600"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1017\/cjn.2021.231","article-title":"Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year","volume":"49","author":"Kernohan","year":"2022","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1017\/cjn.2020.229","article-title":"Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations","volume":"48","author":"McMillan","year":"2021","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Niri, F., Nicholls, J., Baptista Wyatt, K., Walker, C., Price, T., Kelln, R., Hume, S., Parboosingh, J., Lilley, M., and Kolski, H. (2023). Alberta Spinal Muscular Atrophy Newborn Screening\u2014Results from Year 1 Pilot Project. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9030042"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3233\/JND-221561","article-title":"California\u2019s Experience with SMA Newborn Screening: A Successful Path to Early Intervention","volume":"9","author":"Matteson","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajmg.c.32003","article-title":"Georgia State Spinal Muscular Atrophy Newborn Screening Experience: Screening Assay Performance and Early Clinical Outcomes","volume":"190","author":"Elkins","year":"2022","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"ref_35","unstructured":"Lakhotia, A., Toupin, D., Thamann, A., Jackson, K., Sevier, D., Crutcher, A., Wei, S., Arora, V., Asamoah, A., and Robertson, W. (2022, January 2\u20137). Demographic and Clinical Profiles of Neonates Diagnosed with Spinal Muscular Atrophy (SMA) via the Kentucky Newborn Screening (NBS) Program: A Two-Year Experience. Proceedings of the 74th Annual Meeting of the American Academy of Neurology, AAN, Seattle, WA, USA."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Hale, J.E., Darras, B.T., Swoboda, K.J., Estrella, E., Chen, J.Y.H., Abbott, M.A., Hay, B.N., Kumar, B., Counihan, A.M., and Gerstel-Thompson, J. (2021). Massachusetts\u2019 Findings from Statewide Newborn Screening for Spinal Muscular Atrophy. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7020026"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kumar, B., Barton, S., Kordowska, J., Eaton, R.B., Counihan, A.M., Hale, J.E., and Comeau, A.M. (2021). Novel Modification of a Confirmatory SMA Sequencing Assay That Can Be Used to Determine SMN2 Copy Number. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7030047"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","article-title":"Newborn Screening for Spinal Muscular Atrophy in New York State: Clinical Outcomes from the First 3 Years","volume":"99","author":"Lee","year":"2022","journal-title":"Neurology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41436-020-0824-3","article-title":"Implementation of Population-Based Newborn Screening Reveals Low Incidence of Spinal Muscular Atrophy","volume":"22","author":"Kay","year":"2020","journal-title":"Genet. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/gim.2017.152","article-title":"Pilot Study of Population-Based Newborn Screening for Spinal Muscular Atrophy in New York State","volume":"20","author":"Kraszewski","year":"2018","journal-title":"Genet. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kucera, K.S., Taylor, J.L., Robles, V.R., Clinard, K., Migliore, B., Boyea, B.L., Okoniewski, K.C., Duparc, M., Rehder, C.W., and Shone, S.M. (2021). A Voluntary Statewide Newborn Screening Pilot for Spinal Muscular Atrophy: Results from Early Check. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7010020"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nmd.2021.07.398","article-title":"Newborn Screening for Spinal Muscular Atrophy: The Wisconsin First Year Experience","volume":"32","author":"Baker","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.nmd.2023.07.103","article-title":"P221 A Five-Year Review of Newborn Screening for Spinal Muscular Atrophy in the State of Utah: Lessons Learned","volume":"33","author":"Wong","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and Carrier Screening for Spinal Muscular Atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Oliveira Netto, A.B., Brusius-Facchin, A.C., Lemos, J.F., Pasetto, F.B., Brasil, C.S., Trapp, F.B., Saute, J.A.M., Donis, K.C., Becker, M.M., and Wiest, P. (2023). Neonatal Screening for Spinal Muscular Atrophy: A Pilot Study in Brazil. Genet. Mol. Biol., 46.","DOI":"10.1590\/1678-4685-gmb-2023-0126"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100908","DOI":"10.1016\/j.ymgmr.2022.100908","article-title":"Newborn Screening for Spinal Muscular Atrophy in Japan: One Year of Experience","volume":"32","author":"Sawada","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.braindev.2023.03.004","article-title":"Newborn Screening for Spinal Muscular Atrophy in Osaka\u2014Challenges in a Japanese Pilot Study","volume":"45","author":"Kimizu","year":"2023","journal-title":"Brain Dev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kimizu, T., Ida, S., Okamoto, K., Awano, H., Niba, E.T.E., Wijaya, Y.O.S., Okazaki, S., Shimomura, H., Lee, T., and Tominaga, K. (2021). Spinal Muscular Atrophy: Diagnosis, Incidence, and Newborn Screening in Japan. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7030045"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Noguchi, Y., Bo, R., Nishio, H., Matsumoto, H., Matsui, K., Yano, Y., Sugawara, M., Ueda, G., Wijaya, Y.O.S., and Niba, E.T.E. (2022). PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan. Genes, 13.","DOI":"10.3390\/genes13112110"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Shinohara, M., Niba, E.T.E., Wijaya, Y.O.S., Takayama, I., Mitsuishi, C., Kumasaka, S., Kondo, Y., Takatera, A., Hokuto, I., and Morioka, I. (2019). A Novel System for Spinal Muscular Atrophy Screening in Newborns: Japanese Pilot Study. Int. J. Neonatal Screen., 5.","DOI":"10.3390\/ijns5040041"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP Changes upon Symptom Onset and during Treatment in Spinal Muscular Atrophy Patients: Lessons Learned from Newborn Screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genet. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","article-title":"Presymptomatic Diagnosis of Spinal Muscular Atrophy through Newborn Screening","volume":"190","author":"Chien","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lin, Y., Lin, C.H., Yin, X., Zhu, L., Yang, J., Shen, Y., Yang, C., Chen, X., Hu, H., and Ma, Q. (2019). Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.01255"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3343\/alm.2021.41.1.101","article-title":"Detection of Spinal Muscular Atrophy Using a Duplexed Real-Time PCR Approach with Locked Nucleic Acid-Modified Primers","volume":"41","author":"Pan","year":"2021","journal-title":"Ann. Lab. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Liu, Z., Zhang, P., He, X., Liu, S., Tang, S., Zhang, R., Wang, X., Tan, J., Peng, B., and Jiang, L. (2016). New Multiplex Real-Time PCR Approach to Detect Gene Mutations for Spinal Muscular Atrophy. BMC Neurol., 16.","DOI":"10.1186\/s12883-016-0651-y"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mikhalchuk, K., Shchagina, O., Chukhrova, A., Zabnenkova, V., Chausova, P., Ryadninskaya, N., Vlodavets, D., Kutsev, S.I., and Polyakov, A. (2023). Pilot Program of Newborn Screening for 5q Spinal Muscular Atrophy in the Russian Federation. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020029"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Kiselev, A., Maretina, M., Shtykalova, S., Al-Hilal, H., Maslyanyuk, N., Plokhih, M., Serebryakova, E., Frolova, M., Shved, N., and Krylova, N. (2024). Establishment of a Pilot Newborn Screening Program for Spinal Muscular Atrophy in Saint Petersburg. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10010009"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","article-title":"Newborn Screening Programs for Spinal Muscular Atrophy Worldwide: Where We Stand and Where to Go","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/cjn.2023.34","article-title":"Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond","volume":"51","author":"Osman","year":"2024","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Gaviglio, A., McKasson, S., Singh, S., and Ojodu, J. (2023). Infants with Congenital Diseases Identified through Newborn Screening-United States, 2018\u20132020. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020023"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Singh, S., Ojodu, J., Kemper, A.R., Lam, W.K.K., and Grosse, S.D. (2023). Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010\u20132018. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020020"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.nmd.2021.07.008","article-title":"Newborn Screening of Neuromuscular Diseases","volume":"31","author":"Dangouloff","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hale, K., Ojodu, J., and Singh, S. (2021). Landscape of Spinal Muscular Atrophy Newborn Screening in the United States: 2018\u20132021. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7030033"},{"key":"ref_64","unstructured":"Institute for Quality and Efficiency in Health Care (2020). Newborn Screening for 5q-Linked Spinal Muscular Atrophy IQWiG Reports\u2014Commission No. S18-02, Institute for Quality and Efficiency in Health Care."},{"key":"ref_65","first-page":"39","article-title":"Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy","volume":"10","author":"Jedrzejowska","year":"2020","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_66","unstructured":"UK National Screening Committee (UK NSC) (Costello Medical) (2018). Screening for Spinal Muscular Atrophy: External Review against Programme Appraisal Criteria for the UK National Screening Committee (UK NSC), UK National Screening Committee."},{"key":"ref_67","unstructured":"Schroth, M., Friesz, M., Belter, L., Curry, M., and Glascock, J. (2022, January 2\u20137). Implementation of Spinal Muscular Atrophy Newborn Screening Acrossthe US. Proceedings of the 74th Annual Meeting of the American Academy of Neurology, AAN, Seattle, WA, USA."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Aragon-Gawinska, K., Mouraux, C., Dangouloff, T., and Servais, L. (2023). Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening\u2014A Systematic Review. Genes, 14.","DOI":"10.3390\/genes14071377"}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/3\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:17:23Z","timestamp":1760109443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/3\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijns10030049"],"URL":"https:\/\/doi.org\/10.3390\/ijns10030049","relation":{},"ISSN":["2409-515X"],"issn-type":[{"value":"2409-515X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]}}}